Novartis (NYSE:NVS)

Top Analyst Upgrades and Downgrades: DowDuPont, Electronic Arts, Estee Lauder, Exxon, Generac, Match, Nasdaq, Novartis, PayPal, Snap, Vishay and More

Stocks were looking for direction on Wednesday after Tuesday's solid gains. The Dow Jones industrial average is now well over 2,500 points above its lows from the start of January. ...
Read Full Story »

Why Tilray Is Booming

Tilray Inc. (NASDAQ: TLRY) shares made a solid gain on Tuesday after the company announced that it entered a global agreement to collaborate with Sandoz, a subsidiary of Novartis A.G. ...
Read Full Story »

Top Analyst Upgrades and Downgrades: American Air, BlackBerry, Mallinkrodt, PG&E, RingCentral, Southwest Airlines, Yeti and More

  Stocks were indicated to open lower on Monday after weekend news that sounds like a China trade deal is not on the way very soon. Investors have been ...
Read Full Story »

Are Endocyte Investors Getting Enough in the Buyout?

Endocyte Inc. (NASDAQ: ECYT) shares were up sharply on Thursday after it was announced that Novartis A.G. (NYSE: NVS) would acquire the company. The transaction was unanimously approved by the ...
Read Full Story »

6 Most Important Things in Business Today

The founders of Instagram have left the company. According to The New York Times: Kevin Systrom and Mike Krieger, the co-founders of the photo-sharing app Instagram, have resigned and plan ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Baker Hughes, CBS, Generac, Halliburton, Nike, PG&E, Snap, Tesla, Weatherford, Western Digital and More

Stocks were indicated to open lower on Tuesday morning as continued profit-taking in September is a theme. Despite the choppy markets, it's important to know that the major stock ...
Read Full Story »

7 Large Foreign Stocks With Big Upside for US Investors

2018 has been a strange time for investors. While the U.S. stock market sits close to all-time highs, many of the emerging and other developed markets nations have seen their ...
Read Full Story »

Are Some Cancer Treatments Becoming Too Expensive to Approve?

The cure for many types of cancer has been a long road. Many treatments exist for cancer, and defining a cure is often not as simple as it may seem. ...
Read Full Story »

Adamis and Novartis Team Up Against Mylan

Adamis Pharmaceuticals Corp. (NASDAQ: ADMP) saw its shares shoot up early on Monday after the firm announced a partnership with a subsidiary of Novartis A.G. (NYSE: NVS). This was an ...
Read Full Story »

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

It's no surprise that it was only a matter of time before the usage and storage of big data and analytics would come to the health care sector, and many ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Agnico Eagle Mines, Ford, Marathon Petroleum, Roku, Spotify, Quest Diagnostics and More

The futures traded lower this Tuesday morning as investors start the holiday-shortened trading week with continued concerns over trade and additional overseas issues, including growing political instability in Italy. While ...
Read Full Story »

Amgen’s Novel Migraine Treatment Gets Key Approval

Amgen Inc. (NASDAQ: AMGN) shares saw a nice bump after the U.S. Food and Drug Administration (FDA) on Thursday approved Aimovig (erenumab), Amgen's preventive treatment of migraine in adults. It ...
Read Full Story »

Why 4 Top Biotech Stocks May Be the Next Takeover Targets

Last week, Novartis A.G. (NYSE: NVS) announced a huge $8.7 billion all-cash purchase of AveXis Inc.(NASDAQ: AVXS), and many on Wall Street think there is a good chance that mergers ...
Read Full Story »

Novartis Gambles $8.7 Billion on Gene-Therapy Firm

Switzerland-based Novartis A.G. (NYSE: NVS) has agreed to pay $8.7 billion in cash to acquire Illinois-based AveXis Inc. (NASDAQ: AVXS) in a massive bet that the smaller firm's gene-therapy treatment ...
Read Full Story »

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

The concept behind cancer immunotherapy vaccines has been around since, believe it or not, 1891. This is when one Dr. William Coley began directly injecting tumors with bacteria, with 10% ...
Read Full Story »